How People Voted
13% For, 87% Against
Take Action
![]() ![]() |
Alert Your Friends and Colleagues |
![]() ![]() |
Write Your Representative in Congress |
| Save & Share | |
| del.icio.us | |
| Digg | |
| Yahoo! | |
P.L. 110-316, The Animal Drug User Fee Amendments of 2008
- This item is from the 110th Congress (2007-2008) and is no longer current. Comments, voting, and wiki editing have been disabled, and the cost/savings estimate has been frozen.
Comparing revision saved on August 1, 2008, 19:31:47 (webmaster), with revision saved on August 20, 2008, 19:32:29 (webmaster):
H.R. 6432 would amend the Federal Food, Drug, and Cosmetic Act to revise and extend the animal drug user fee program.
== Detailed Summary ==
<summary>
(Log<b>(This measure has not been amended since it was passed by the House on July 30, 2008. The summary of that version is repeated here.)</b>
<b>Title I: Animal Drug User Fee Amendments</b> - Animal Drug User Fee Amendments of 2008 - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act to revise definitions, including defining the "process for the review of animal drug applications" to include the review of advertising and labeling prior to an approval of an animal drug application or supplemental animal application after the animal drug has been approved.
(Sec. 103) Requires the Secretary of Health and Human Services to assess 50% of the standard fee for a new animal drug application for a drug that combines active ingredients that have been approved separately.
Sets forth the amount of revenue that animal drug application fees, supplemental and other animal drug application fees, product fees, establishment fees, and sponsor fees are to generate for FY2009-FY2013.
(Sec. 104) Requires the Secretary to report to Congress and make publicly available information on: (1) progress toward the goal of expediting the animal drug development process and the review of animal drug applications; and (2) implementation of the authority for and use of animal drug fees.
Sets forth a process for the Secretary to develop recommendations for the process of review of animal drug applications after FY2013.
(Sec. 105) Requires the sponsor of any new animal drug that contains an antimicrobial active ingredient to annually report to the Secretary on the amount of each antimicrobial active ingredient in the drug that is sold or distributed for use in food-producing animals, including information on any distributor-labeled product. Authorizes the Secretary to editshare such information with the wikiAntimicrobial Resistance Task Force.
(Sec. 108) Terminates the authority to collect and assess animal drug fees on October 1, 2013. Terminates reporting requirements on January 31, 2014.
<b>Title II: Animal Generic Drug User Fee</b> - Animal Generic Drug User Fee Act of 2008 - (Sec. 202) Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary to assess and collect fees for an abbreviated application for a generic new animal drug, including application fees, product fees, and sponsor fees.
Sets forth total revenue to be collected for each type of fee for FY2009-FY2013.
Provides for fee adjustments. Requires the firstSecretary to establish such fees each fiscal year.
Provides for fee waivers where the Secretary finds that the generic new animal drug is intended solely to provide for a detailed summaryminor use or minor species indication.
Authorizes appropriations for FY2009-FY2013.
(Sec. 203) Requires the Secretary to report to Congress and make publicly available information on: (1) progress toward the goal of expediting the generic new animal drug development process and the review of abbreviated applications for such drugs; and (2) the implementation of the authority for and use of generic new animal drug fees.
Sets forth the process for developing recommendations to present to Congress for the review of abbreviated applications for generic new animal drugs after FY2013.
(Sec. 204) Terminates the authority to assess and use generic new animal drug fees on October 1, 2013. Terminates reporting requirements on January 31, 2014.
<b>Title III: Technical Corrections to FDAAA</b> - (Sec. 301) Amends the Federal Food, Drug, and Cosmetic Act to require that consideration of a citizen petition or a petition for a stay of agency action on a new drug application be separate and apart from review and approval of any such application.
(Sec. 302) Amends the Public Health Service Act to make technical corrections to provisions related to the bill!)clinical trials data bank.
</summary>
<!--Leave in the 'summary' tags if you want the latest summary from the Congressional Research Service automatically to replace the text between the tags once it becomes available. -->
== Status of the Legislation ==
<status>
Latest Major Action: 7/31/2008: Received in the Senate.8/6/2008: Presented to President.
</status>
<!-- Leave in the 'status' tags if you want the latest reported status from THOMAS automatically to replace the text between the tags once it becomes available. -->
== Points in Favor ==
(Log in to edit the wiki and be the first to show why the bill should pass!)
<!-- First editor: Go ahead and take out the sentence in parentheses, and this notice! -->
== Points Against ==
(Log in to edit the wiki and be the first to show why the bill should not pass!)
<!-- First editor: Go ahead and take out the sentence in parentheses, and this notice! -->
Cost per :
Learn More
There was no up-or-down vote in the House.
There was no up-or-down vote in the Senate.
RSS Feeds for This Bill
Keep yourself updated on user contributions and debates about this bill! (Learn more about RSS.)




Visitor Comments
There are currently no comments for this bill.